Pfizer Inc. Stock

If it weren't for question marks about its future growth, Pfizer (NYSE: PFE) stock would undoubtedly be trading at a much higher price. Sales were down last year, and the stock has been floundering,

Pharmaceutical giants Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are still the two titans of the weight loss drug market, to be sure. Lilly sold $13.5 billion worth of GLP-1-based Zepbound

If you keep regular tabs on pharmaceutical giant Pfizer (NYSE: PFE), then you know it hasn't yet restored the revenue lost due to the wind-down of the COVID-19 pandemic; the world just doesn't need

The S&P 500 index (SNPINDEX: ^GSPC) has a tiny yield of 1.1%. The average pharmaceutical company's yield is 1.7%. Those comparison points make Pfizer's (NYSE: PFE) 6.7% dividend yield look

When it comes to pharmaceutical stocks and yield, Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) stand out. However, when deciding which of the two is the better high-yield dividend stock

If you have $1,000 that you can afford to invest in the stock market, dividend stocks can help make the most of your money, specifically those that are trading at low valuations. While buying Nvidia

Over the past few years, Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE), have underperformed broader equities. However, throughout it all, they have maintained their dividend programs

Savvy investors know that change creates opportunities. And a major change is underway at the nation's central bank. Kevin Warsh is now the new Federal Reserve Chair, taking the baton from Jerome

Pfizer (NYSE: PFE) was founded in 1849. That makes the company well over 100 years old. Not many companies have managed to survive as long as Pfizer has, especially in an industry as highly

Wall Street analysts have to answer to their bosses every day, which can make it hard to take a long-term view of a business. How do you justify a buy rating on a company when its stock is

Pfizer (NYSE: PFE) is facing patent expirations for some of its biggest drugs. That's normal for a pharmaceutical company, but Pfizer doesn't appear to have any major new drugs to replace those

If you've spent any time reading about certain stocks, you'll have noticed that opinions among Wall Street analysts can vary widely. Because there's no way to definitively determine where a stock

When you think of growth stocks, you may immediately think of technology. But this isn't the only field delivering significant revenue gains these days. In fact, you'll find one of the biggest

A company with a $140 billion market cap is very large. It is also highly likely to be an important player in the industry where it competes. But that doesn't seem to matter today for Pfizer (NYSE:

Shares of Bristol Myers Squibb (NYSE: BMY) are trading in a manner that evokes little confidence in the company's future growth.

The numbers suggest otherwise. At roughly 10 times forward earnings